Spots Global Cancer Trial Database for Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
Official Title: Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Study ID: NCT00557206
Interventions
Study Description
Brief Summary: Patient receiving oxaliplatin and docetaxel will have longer progression free survival than those patients receiving standard care.
Detailed Description: Oxaliplatin: 130mg/m2 given on day 1 by intravenous injection; and Docetaxel: 60mg/m2 given on day 1 by intravenous injection Cycles are repeated every 21 days until disease progression, unacceptable toxicity or subject's withdrawal.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
VA Medical Center, Minneapolis, Minnesota, United States
Contact Details
Name: Balkrishna Jahagirdar, MD
Affiliation: Minneapolis Veterans Affairs Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: Vicki A Morrison, MD
Affiliation: Minneapolis Veterans Affairs Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
